61.8
Avalo Therapeutics, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
Assets
(positive)
Change from FY21 to FY25
millions USD
FY21:
FY22:
16.4
FY23:
8.40
FY24:
139
FY25:
105
(positive)
Change from FY21 to FY25
millions USD
FY21:
18.4
FY22:
17.0
FY23:
12.6
FY24:
11.8
FY25:
11.2
Total assets
Change from FY21 to FY25
millions USD
FY21:
80.2
FY22:
33.4
FY23:
21.0
FY24:
151
FY25:
116
Liabilities & Equity
(negative)
Change from FY21 to FY25
millions USD
FY21:
19.9
FY22:
22.1
FY23:
4.62
FY24:
6.96
FY25:
12.9
(negative)
Change from FY21 to FY25
millions USD
FY21:
37.2
FY22:
22.2
FY23:
9.07
FY24:
10.7
FY25:
20.5
(positive)
Change from FY21 to FY25
millions USD
FY21:
23.1
FY22:
−10.9
FY23:
7.30
FY24:
133
FY25:
83.0
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
80.2
FY22:
33.4
FY23:
21.0
FY24:
151
FY25:
116
All amounts in millions USD